Technology areas: Biotechnology & Pharmaceuticals • Communications
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
UNIVERSITY HOSPITALS CLEVELAND MEDICAL CENTER currently has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are being reviewed by 3 distinct examiners, indicating that each active application is under the care of a different official. The portfolio is spread across 3 distinct art units, which suggests that the center's medical research touches on several different specialized fields. This variety requires a flexible and multifaceted approach to patent prosecution.
LEWOCZKO, EVAN MICHAEL is the busiest examiner for this portfolio, currently overseeing 1 busiest examiner pending action. Since there are 3 pending office actions and 3 distinct examiners, the workload is perfectly distributed with no examiner handling more than one case. This means the institution must manage three separate relationships and examination styles. The 1 busiest examiner pending action shows that even the most active examiner has a limited impact on the overall portfolio.
The involvement of 3 distinct art units means the legal strategy must account for the specific nuances of three different technical groups. With 3 pending office actions, the center has a moderate level of activity at the patent office. Practitioners should be ready to address a diverse set of examiner concerns across the biotechnology sector. This profile indicates a portfolio that is expanding into multiple technical niches within the medical field.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LEWOCZKO, EVAN MICHAEL | 1 | — | — |
| GEBRESLASSIE, WINTA | 1 | 77.6% | +20.1% |
| DUTT, ADITI | 1 | 46.8% | +48.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18727234 | SYSTEMS AND METHODS OF GENERATING LIPID, PROTEIN, AND/OR PROTEIN SHELLED BUBBLES | LEWOCZKO, EVAN MICHAEL | — |
| 17790480 | Biomarker and Druggable Target of Neurodegeneration | DUTT, ADITI | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18651752 | RISK PREDICTION OF HEART FAILURE | GEBRESLASSIE, WINTA | — |
| 17790480 | Biomarker and Druggable Target of Neurodegeneration | DUTT, ADITI | — |
| Art Unit | Apps |
|---|---|
| 1612 | 1 |
| 2677 | 1 |
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18727234 | SYSTEMS AND METHODS OF GENERATING LIPID, PROTEIN, AND/OR PROTEIN SHELLED BUBBLES | LEWOCZKO, EVAN MICHAEL | 1612 | §102§103§112 | Non-Final OA | — | Pending | Jul 08, 2024 |
| 18651752 | RISK PREDICTION OF HEART FAILURE | GEBRESLASSIE, WINTA | 2677 | §103 | Final Rejection | — | Pending | May 01, 2024 |
| 17790480 | Biomarker and Druggable Target of Neurodegeneration | DUTT, ADITI | 1675 | §103§112 | Final Rejection | — | Pending | Jun 30, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialUNIVERSITY HOSPITALS CLEVELAND MEDICAL CENTER has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Evan Michael Lewoczko has the most, with 1 of UNIVERSITY HOSPITALS CLEVELAND MEDICAL CENTER's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
